A lthough many proteins show changes in their function at very high alcohol concentrations (Ͼ50 mM), the molecular basis for behavioral alcohol effects at low to moderately intoxicating doses experienced during social alcohol consumption remains elusive (1) . GABA A receptors (GABA A Rs) and the inhibitory GABAergic system have long been suspected to be targets for acute alcohol effects (2) (3) (4) . For example, the GABA A R agonist muscimol potentiates the sedative actions of alcohol, whereas the opposite effect, a reduction of ethanol (EtOH)-produced sedation, is detected with the GABA A R blockers picrotoxin and bicuculline (5) . Although most GABA A R subunit combinations can be activated by high (anesthetic) alcohol concentrations (6) , only very specific GABA A R subunit combinations (containing the ␦ as well as the ␤ 3 subunit) exhibit dose dependencies that mirror blood alcohol levels that are associated with mild to moderate intoxication in humans (7, 8) (Ϸ3-30 mM, because the legal drinking limit is 17 mM or 0.08%). GABA A Rs containing the ␦ subunit are located either outside (9) or in the perimeter of (10) synapses but not in the subsynaptic membrane, and they give rise to a persistent (tonic) GABA current (11) that is enhanced by low alcohol concentrations (12) (13) (14) . However, there is controversy because Carta et al. (14) concluded that the EtOH-induced increase in tonic current is due to increased GABA release rather than a postsynaptic effect. Also, for reasons on which we can only speculate, a recent article by Borghese et al. (15) states that effects of low dose EtOH on ␦ subunit-containing receptors could not be observed, in particular with human ␣ 4 ␤ 3 ␦ GABA A R clones expressed in oocytes and cell lines.
EtOH pharmacology shares many characteristics with allosteric activators of GABA A Rs (loosely referred to as GABA A R agonists), such as benzodiazepines (BZs) (5) . Additional evidence for a link between EtOH and BZ actions on GABA A R comes from the surprising finding that a mutation in the ␣ 6 subunit (␣ 6 -R100Q), which was identified in alcohol-nontolerant and -nonpreferring rats in refs. 16 and 17, leads to receptors with increased alcohol sensitivity in recombinant expression (in cerebellar granule cell neurons) and to alcohol-hypersensitive animals in behavioral studies (12) . Histidine residues at positions that are homologous to the ␣ 6 -R100 residue (which affects EtOH sensitivity in ␣ 6 ␤ 3 ␦ GABA A Rs) are critical for high-affinity binding of classical BZ agonists at the interface between ␣ and ␥ 2 subunits.
It has been thought that the ''extrasynaptic'' GABA A R ␦ subunit, which presumably takes the position of the ␥ 2 subunit in functional pentameric GABA A Rs, renders receptors insensitive to BZs (18) . Also, most ␦ subunits are found to be associated with ␣ 4 and ␣ 6 subunits that differ from other GABA A R ␣ subunits at a critical position (a histidine in ␣ 1,2,3,5 replaced by an arginine in ␣ 4, 6 ) that makes ␣ 4/6 ␤ x ␥ 2 receptors insensitive to classical BZ agonists such as diazepam (DZ) and flunitrazepam (19, 20) . However, Arg-100 (WT) in ␣ 4 and ␣ 6 receptors still allows high-affinity binding of the imidazo-BZs Ro15-4513 and flumazenil (in ␣ x ␤ x ␥ 2 GABA A Rs). In functional receptor assays, Ro15-4513 is a weak partial inverse agonist (i.e., it leads to a slight reduction in GABA A R activity) on the most abundant GABA A R subtypes in the brain (20) . Ro15-4513 is a partial agonist (i.e., it enhances GABA action, but less than DZ even at saturating concentrations) on the ␣ 4 and ␣ 6 receptors (with ␤ and ␥ 2 subunits), whereas flumazenil is essentially silent in functional assays. Interestingly, Ro15-4513, but not other inverse agonists [like the ␤-carbolines ␤-carboline-3-carboxyethyl ester (␤-CCE) and methyl-6,7-dimethoxy-4-ethyl-␤-carboline-3-carboxylate (DMCM)], has been shown to have fairly dramatic alcoholantagonist actions, reported in various mammals; in particular, alcohol effects at lower doses can be reversed almost completely by Ro15-4513 (3, (21) (22) (23) (24) (25) .
Here, we show that alcohol-sensitive ␣ 4/6 ␤ 3 ␦ GABA A Rs bind [ 3 H]Ro15-4513 with high affinity, and that this binding is inhibited dose-dependently by low doses of EtOH. This result is consistent with the observation that Ro15-4513 potently inhibits EtOH enhancement of functional ␣ 4/6 ␤ 3 ␦ GABA A Rs (45) . The Ro15-4513͞EtOH antagonism appears to be competitive. Importantly, our data explain the puzzling observation that Ro15-4513 is a behavioral alcohol antagonist and suggest that EtOH͞ Ro15-4513-sensitive GABA A Rs are important mediators of alcohol actions that are experienced during moderate social drinking.
Results

Alcohol Antagonist Ro15-4513 Binds to ␦ Subunit-Containing
GABAARs. Based on the observations that ␦ subunit-containing receptors are uniquely sensitive to EtOH (7) , and that a BZ-site single-nucleotide polymorphism (␣ 6 -R100Q) increases alcohol sensitivity in ␣ 6 ␤ 3 ␦ receptors (12), we decided to investigate whether native and recombinant ␦ subunit-containing receptors could bind the behavioral alcohol antagonist Ro15-4513, which is commercially available as a tritiated radioligand.
To study native receptors, we immunopurified ␦ subunitcontaining GABA A Rs from cow cerebellum. The most likely subunit composition of these immunopurified receptors is ␣ 6 ␤␦. Based on the high EtOH sensitivity of cerebellar tonic currents and the increase in alcohol sensitivity observed with the ␣ 6 -R100Q allele, it seems likely that most of these receptors contain the ␤ 3 subunit (12 
Binding of [
3 H]Ro15-4513 to GABA A Rs in the cerebellum has been considered to include sites that are sensitive to classical BZ agonists (DZ-S binding) on ␣ 1 ␤␥ 2 isoforms and DZ-insensitive (DZ-IS) binding sites observed in the presence of 10-100 M DZ. The latter are thought to be largely composed of ␣ 6 ␤␥ 2 subunits (26) (27) (28) . Based on our finding that ␦ subunit-containing GABA A Rs bind [ 3 H]Ro15-4513 with high affinity, and that this binding is sensitive to displacement by EtOH, we reasoned that a fraction of the DZ-IS binding sites in brain might be due to ␦ subunit-containing receptors. In agreement with previous stud- ies (29) , Ϸ20% of the [ 3 H]Ro15-4513 binding to cerebellar membranes was not blocked by 10 M DZ (Fig. 2b Inset). Of this DZ-insensitive [ 3 H]Ro15-4513 binding, Ϸ30% was dosedependently inhibited by EtOH (IC 50 Ϸ 7 mM), with a maximum inhibition at 100 mM EtOH (Fig. 2b) . Given that DZ-IS binding of [ 3 H]Ro15-4513 in the cerebellum is Ϸ20% of total binding, EtOH-displaceable Ro15-4513 binding is Ϸ6% of total cerebellar Ro15-4513 binding. This percentage is consistent with the ␦ Ab-precipitated fraction, enriched in ␣ 6 ␤␦ receptors and in the same range as the fraction of ␣ 6 ␤ x ␦ receptors (Ϸ11%) determined by biochemical methods in rat cerebellum (30 (Fig. 3) . The simultaneous least-square fit using a combined Hill͞Schild-Gaddum equation (with K d ϭ 7.5 nM for Ro15-4513) resulted in a Hill coefficient of 1.1 and a K d ϭ 8.1 mM for EtOH (colored curves in Fig. 3 ). That the prediction for competitive antagonism overlaps with our experimental data provides additional evidence that alcohol and Ro15-4513 are likely to occupy overlapping binding sites.
The decrease in receptor occupancy in the presence of competitive antagonists, as described by the Schild-Gaddum equation, is due to a reduction in the apparent association rate of ligands (binding sites occupied by the competitive ligand are not available for binding), without changes in the dissociation rate (i.e., the residence time of ligands in their binding sites). Therefore, we decided to determine the dissociation rate of (22, 31) and the imidazo-BZs (Ro15-4513͞flumazenil structural analogs) RY024 and RY080. RY024 has been described as a behavioral alcohol antagonist (32, 33) . We show that like ''cold'' Ro15-4513, flumazenil, RY024, and RY080, and the ␤-carbolines ␤-CCE and FG7142, displaced [ 3 H]Ro15-4513 from its binding site on ␣ 4 ␤ 3 ␦ receptors (Fig. 4) . Therefore, ligands that block EtOH enhancement of ␣ 4͞6 ␤ 3 ␦ GABA A R currents, such as Ro15-4513, or that reverse the alcohol-antagonist activity of Ro15-4513 (f lumazenil and ␤-CCE) (21, 29, 45) , are also able to displace tors do not displace [ 3 H]Ro15-4513 from this binding site on ␦ receptors at reasonable concentrations ( Fig. 5 and Table 1 ). This observation is consistent with the notion that these compounds will not prevent the alcohol-antagonist activity of Ro15-4513. The GABA A R channel antagonist picrotoxinin (100 M) did not inhibit binding.
Flumazenil, Ro15-4513, and RY080 all differ only at the moiety at the C7 position (blue in Fig. 5 ; fluorine in flumazenil, an azido group in Ro15-4513, and an acetylene group in RY080). The less potent compound RY024 is identical to RY80 except that it contains the carboxy-t-butyl ester instead of the carboxyethyl ester moiety. Also, the only difference between FG7142 and ␤-CCE is that the lower-affinity compound FG7142 carries a carboxymethyl amide instead of a carboxyethyl ester. Therefore, it is likely that the carboxyethyl ester moiety (green in Fig.  5) , which is present in all compounds with affinities of K d Յ 10 nM (Table 1) , is important for high-affinity binding to the alcohol͞BZ site in ␣ 4͞6 ␤ 3 ␦ receptors. The lack of affinity of classical BZ agonists and DMCM could be due to the absence of the carboxyethyl ester group at the appropriate location. Also, chemical moieties in these inactive compounds (e.g., the pendant phenyl group in classical BZs; red in Fig. 5 ) may lead to steric hindrance.
Discussion
We show that native immunopurified and recombinantly expressed ␦ subunit-containing receptors bind the imidazo-BZ Ro15-4513 (and flumazenil) with high affinity in binding assays, and that Ro15-4513 binding is abolished not only by the ␤-carboline BZ-site ligands ␤-CCE and FG7142 but also by low concentrations of EtOH. It is a widely held notion that the BZ ligand-binding site is limited to the ␣-␥ 2 interface, and ␦ subunit-containing receptors are insensitive to all BZ site ligands, based on reports that agonists like DZ and flunitrazepam did not enhance expressed ␦-containing receptor currents (18, 34) . Therefore, the discovery that certain BZ-site ligands can bind with high affinity to ␦ subunit-containing receptors is surprising.
Additional BZ-binding sites, such as the Ro15-4513͞EtOH site on ␣ 4/6 ␤ 3 ␦ receptors described here, might contribute to the diverse pharmacological properties of clinically used BZ site ligands. This BZ͞EtOH site on ␣ 4/6 ␤ 3 ␦ receptors was difficult to detect because these receptors are of relatively low abundance, and (like the BZ sites on ␣ 4/6 ␤␥ 2 GABA A Rs) they are essentially insensitive to classical BZ site agonists (e.g., DZ, flunitrazepam, midazolam, and flurazepam). Also, binding of the high-affinity BZ ligand Ro15-4513 to these GABA A R subtypes is functionally silent (18) and, therefore, usually remains undetected in functional assays.
Our data are consistent with a competitive model of interaction between EtOH and Ro15-4513, suggesting that EtOH and Ro15-4513 occupy overlapping binding sites. In support of this concept, we showed that increasing concentrations of EtOH led to a complete inhibition of [ 3 H]Ro15-4513 binding to recombinant ␦ subunit-containing receptors, whereas binding of [ 3 H]Ro15-4513 to ␥ 2 subunit-containing receptors was not inhibited by EtOH. We also showed that, as expected from a simple competition for an overlapping binding site, the apparent affinity for Ro15-4513 was decreased in the presence of EtOH. Additional support for a competitive model comes from analysis of the unbinding reaction of [ 3 H]Ro15-4513. As expected for a competitive antagonism, excess EtOH (like excess cold Ro15-4513) led to virtually identical unbinding rates.
Structurally, Ro15-4513 is identical with the clinically used general BZ antagonist flumazenil, except that flumazenil carries a fluorine atom at position C7 of the BZ ring, whereas Ro15-4513 carries the larger azido group (Fig. 5) . Given this structural similarity with flumazenil, it is not surprising that Ro15-4513 also binds with high affinity to the classical BZ sites and antagonizes the actions of classical BZ agonists (35) , and that flumazenil (which by itself does not have alcohol-antagonist activity) can overcome the behavioral alcohol-antagonistic activity of Ro15-4513 (3, 22) . Our results suggest that flumazenil, as well as ␤-CCE and FG7142, counteract the behavioral alcohol antagonism of Ro15-4513, because they displace Ro15-4513 from its binding site on ␦ subunit-containing receptors.
Also, that (i) Ro15-4513 and flumazenil differ only at the C7 position of the BZ ring structure, (ii) Ro15-4513, but not f lumazenil, shows alcohol-antagonist properties, and (iii) Ki values were determined based on the ability to displace K i values above 1,000 nM are grouped into two categories: less than 10% inhibition (Ͼ Ͼ1,000) and between 10% and 50% inhibition at 1,000 nM (Ͼ1,000). 
Therefore, we propose a model in which the azido group (which is approximately the same size as alcohol) occupies the EtOHbinding pocket in the Ro15-4513-bound receptor and thus prevents EtOH binding to these types of GABA A Rs. Consistent with this view, there have been recent reports of in vivo alcoholantagonist actions of the Ro15-4513͞f lumazenil derivative RY024; RY024 and the related molecule RY080 have an acetylene group (instead of an azido group) at the C7 position of the BZ ring (32) . We found that these chemical analogs of Ro15-4513 (RY024 and RY080) are potent inhibitors of [ 3 H]Ro15-4513 binding to this alcohol͞BZ site. This inhibition suggests that the reported behavioral alcohol antagonism of RY024 may be due to reversal of alcohol actions on unique EtOH͞BZ-sites on GABA A Rs.
Photolabeling, site-directed mutagenesis, cysteine-accessibility studies, and BZ pharmacophore models derived from those data lead to the consensus that side-chain residues at the C7 position of the BZ ring are close to the critical histidine residue (␣ 1 -H102, bovine numbering) that determines sensitivity of ␣ 1,2,3,5 -containing receptors to classical BZ agonists in ␣␤␥ 2 receptors (36) (37) (38) (39) (40) . The selective labeling, by the photoreactive C7 azido group of Ro15-4513, of tyrosine ␣ 1 -Y210 (bovine numbering) (37) , which is in close proximity to ␣ 1 -H102 in structural homology models (37, 38, 41) , is probably due to a higher photoreactivity of tyrosine residues (37) .
The residue homologous to ␣ 1 -H102 in ␣ 6 is polymorphic in rats and can be ␣ 6 -R100 or ␣ 6 -Q100. We showed that the ␣ 6 -100Q polymorphism, which has been selected for during breeding of alcohol hypersensitive (alcohol-nontolerant) rats (16) , leads to a dramatically increased alcohol sensitivity of ␣ 6 -100Q␤ 3 ␦ GABA A R in vitro and in vivo (12) . Based on our findings described here, it is tempting to speculate that the reason for the increased alcohol sensitivity of ␣ 6 -100Q␤ 3 ␦ receptors (and ␣ 6 -100Q͞Q rats) is that the ␣ 6 -100 residue is very close to, and might even directly line, the EtOH-binding site.
The data presented here strongly support the view that the alcohol-antagonist action of Ro15-4513 is largely due to specific actions on alcohol-sensitive subtypes (like ␣ 4/6 ␤ 3 ␦) of GABA A Rs. It remains to be determined whether the partial inhibition (inverse agonist action) of Ro15-4513 on some GABA A R subtypes contributes to this alcohol antagonism. However, the fact that other inverse agonists (e.g., FG7142 and ␤-CCE) are not alcohol antagonists (22, 24, 42) suggests that such a contribution from action on other GABA A R subtypes is only minor. The inverse agonists FG7142 and ␤-CCE (like flumazenil) reverse the behavioral alcohol antagonism of Ro15-4513 (22, 31) and displace Ro15-4513 from the EtOH͞Ro15-4513 site on ␣ 4/6 ␤ 3 ␦ receptors. Although the relative contributions of individual GABA and non-GABA receptors to the various aspects of EtOH intoxication, as well as whether there are other unrecognized subtypes of GABA A Rs that are also sensitive to EtOH͞Ro15-4513 that may contribute to Ro15-4513-sensitive behavioral EtOH effects, remain to be determined, the results presented here strongly support the view that EtOH͞Ro15-4513-sensitive GABA A Rs are important mediators of alcohol actions at blood-alcohol concentrations that are experienced during low and moderate alcohol consumption. Also, the competitive nature of the EtOH-Ro15-4513 interaction on ␦ subunit-containing GABA A R might allow us to determine where in the receptors the EtOH-binding site is located. The displacement of Ro15-4513 from ␣ 4/6 ␤ 3 ␦ receptors provides a test-tube assay to screen for ligands that can bind to, or very close to, the EtOH-binding site that mediates behaviorally relevant low dose EtOH effects. This binding assay allows further structure-function analysis of the pharmacological potency and efficacy of compounds that are active at the ''alcohol receptor.'' Ligands that are active at the alcohol͞BZ binding site on ␦ subunit-containing GABA A R receptors may yield therapeutics for problems that are related to low dose EtOH sensitivity, including anxiety, insomnia, and alcoholism. Membrane Preparation. Bovine cerebellum was obtained from a local supplier and stored frozen at Ϫ70°C. Tissue was thawed and homogenized by sonication in 10 volumes of homogenization buffer [50 mM Tris⅐HCl, pH 8.0͞50 mM KCl͞1 mM EDTA͞0.32 M sucrose͞0.5 mM DTT͞0.01% bacitracin supplemented with either protease inhibitors (2 mM benzamidine͞0.1 mM benzethonium chloride͞0.3 mM PMSF) or a protease inhibitor mixture (Complete Mini, Roche Diagnostics)] and centrifuged (550 ϫ g) for 10 min at 4°C to pellet nuclei and cells. The supernatant fraction was collected by three sonication-centrifugation cycles (in homogenization buffer without sucrose). Membrane pellets were collected at 35,000 ϫ g for 1 h at 4°C and used for ligand binding, or they were stored frozen at Ϫ20°C.
Methods
Radiolabeled
Recombinant Cell Expression. HEK 293T cells were transfected with rat cDNAs under the control of a CMV promoter (␣͞␤͞␦ or ␥ 2 , 1:1:2) as described in ref. 43 , and cells were harvested at 60-100 h after transfection. Membranes from these HEK 293T pellets were homogenized by sonication in 10 volumes of assay buffer (100 mM KCl͞10 mM KH 2 PO 4 ͞K 2 HPO 4 , pH 7.5, at 4°C) with a protease inhibitor mixture (Complete Mini) and subjected to three centrifugation-resuspension cycles before being used for ligand binding assays.
[ 3 H]Ro15-4513 Ligand Binding Assay. Membranes (or IP receptors bound to protein G-agarose beads) were resuspended in assay buffer (50 mM Tris⅐HCl, pH 8.0͞1 M KCl͞1 mM EDTA͞0.5 mM DTT͞2 mM benzamidine͞0.01% bacitracin͞0.3 mM PMSF͞10 g/ml trypsin inhibitor) by sonication. Resuspended membranes were incubated (in a volume of 0.5 ml) for 60 min on ice in the presence of [ 3 H]Ro15-4513 (33.3 Ci͞mmol, PerkinElmer) and various concentrations of competing ligands. Membranes (10-40 g of protein per filter) were collected by rapid filtration on GF͞B filters (Whatman). After three washing steps with 10 ml of assay buffer, the filter-retained radioactivity was counted in a LS3800 liquid scintillation counter (Beckman). Nonspecific binding was determined in the presence of 10 M Ro15-4513, and DZ-IS binding was determined in the presence of 10 M DZ. Data for binding curves were fitted by using a nonlinear least-squares method with the following equations: B(c) ϭ B max ͞ (1 ϩ (K d ͞c) n ), for binding curves, and B(c) ϭ B max ͞(1 ϩ (c͞ IC 50 ) n ), where c is the concentration of ligand, B is binding, B max is maximal binding, K d is the dissociation constant, n is the Hill coefficient, and IC 50 is the half-maximal inhibitory concentration. These calculations were performed by using PRISM (GraphPad, San Diego) software. All error bars in the figures indicate SD.
Immunoprecipitation (IP).
IPs were performed from membrane preparations solubilized in assay buffer (as described above), supplemented with 8 mM of the nonionic detergent nonaoxyethylene dodecyl ether (C12E9), by using rabbit GABA A R ␦ subunit-specific Ab (30) and the protein G IP50 IP kit (Sigma). Briefly, 100 l (Ϸ1 g͞l) of protein extracts were incubated in 600 l of IP buffer plus 60 l of 0.5 M NaCl with Ab (at appropriate dilutions) overnight at 4°C. After the addition of 30 l of protein G-agarose, the tubes were incubated for an additional 2 h with mixing. The beads were washed five times with cold IP buffer, and binding assays were performed on Ab-bound receptors (30) .
